PPT Slide

Problems

• Safety / Unexpected toxicity (PMS)

• Commercial benefits =  flu-like syndroms, URTI, AECB

• Massive use = resistance among respiratory pathogens among commensal gut-flora

Fluoroquinolones

Previous slide

Next slide

Back to first slide

View graphic version